LIQUIDIA CORP

Liquidia Corporation (LQDA) is a clinical-stage biopharmaceutical company focused on designing and developing inhaled and targeted medicines using its proprietary PRINT particle-engineering platform. The company aims to improve delivery, dosing consistency and tolerability for respiratory and other conditions through dry-powder and precision-formulated therapies. Investors should be aware that value is heavily tied to clinical trial outcomes, regulatory decisions and potential commercial adoption; revenues may be limited until approval and launch. With a market capitalisation near $2.03 billion, Liquidia can offer upside if its pipeline advances, but also carries significant development, regulatory and commercial risks. Key factors to watch include clinical readouts, partnership agreements, manufacturing scale-up and intellectual-property protection. This summary is for educational purposes and not personalised investment advice — past performance is not a reliable indicator of future results and capital is at risk.